Skip to main content
Premium Trial:

Request an Annual Quote

Kreatech, LUMC Co-developing Tumor Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dutch molecular diagnostics shop Kreatech Diagnostics announced today a co-development deal with Leiden University Medical Center directed at fluorescent in situ hybridization probes for genetic targets in bone and soft tissue tumors.

Biomarkers resulting from research conducted at LUMC will be used to design and commercialize diagnostic tests for the differential diagnosis of tumors and as companion diagnostics, Kreatech said. LUMC will validate the probes and Kreatech will manufacture and commercialize them.

Further terms of the deal were not disclosed.

The first three probes, which will focus on sarcoma diagnostics, are expected to be launched this year. The two partners also intend to develop a range of FISH probes for the pathology field.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.